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Petra Helbig4, Andrey Antov4, Jens Rueter4, Paul Han1
1Center

Background
• Genomic tumor testing (GTT) is a new technology and a
cornerstone of the “precision medicine” movement in cancer
care.
• GTT uses next-generation genome sequencing technology to
identify somatic variants in tumor cells.
• By identifying somatic variants that predict responses to cancer
therapies, GTT can help tailor therapy to individual patients,
making them more effective.
• However, due to the fact that GTT also detects many variants of
uncertain significance, its clinical value is currently unproven.
• When using GTT, physicians counsel patients about both its
benefits and its limitations, but the ideal goals and content of
these physician-patient discussions have not been clearly
defined.
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Results

Participants
Provider-patient discussion about genomic tumor testing
Managing patient expectations of
the value of testing

Explain the nature of testing
o

Scientific explanation

• Assess and attend to patient literacy

o

Testing process

o

Type of test – somatic vs.

• Discuss likelihood of benefit

Provider language used in discussing
value of testing

germline

Certain Value
Positive Sentiment

Negative Sentiment
• “Does not”

• “Will”

Goals and purpose of testing
o

Treatment planning

Objective

o

Diagnostic use

Explore providers’ perceptions of the key goals and elements of
physician-patient discussions about GTT.

o

Prognostic use

Uncertain Value
Positive Sentiment
• “Can”

Negative Sentiment Balanced Sentiment
• “May or may not”

• “Might not”

Methods
• Qualitative analysis of open-ended responses to questionnaire
administered to health professionals participating in the
Jackson Laboratory’s Maine Cancer Genomics Initiative (MCGI),
a 5-year state-wide research project aimed at disseminating
and implementing GTT in community oncology practices
throughout the state of Maine.
• In April 2018, 120 physicians and clinical staff attended an
annual 2-day MCGI conference, convened by The Jackson
Laboratory to educate and update providers on the progress of
the initiative.
• Surveys consisted of both multiple-choice and open-ended
questions, designed to assess perceptions of the key goals and
elements of physician-patient discussions of GTT.
Open-ended question (Key elements)
“Given what you know about GTT, how would you introduce it to a
patient? Identify three (3) essential things the patient needs to
know.”
• Qualitative thematic analysis of open-ended items, softwareassisted coding with MAXQDA™

Illustrative Quotations from Open-Ended Responses
Scientific explanation

“The reason that cancers that look the same don’t respond the same is because of different
genetic changes inside the cancer cell”

Testing process

“Testing done on tumor tissue removed during surgical procedure”

Type of test

“Whether the test will focus on tumor or both tumor and germline”

Treatment Planning

Certain Value

Uncertain Value

“This is a way to utilize precision medicine and
offer a more personalized treatment based on
cancer genomics and identifying specific genes
and mutations associated with patient’s
individual cancer”

“We hope the result will help guide future
treatment options, however we do not always
find mutations that we can take action on or
change treatment”

Diagnostic Use

“Different than genetic testing, will classify
tumor”

“Real chance that test may not yield any results
or may yield results that are vague or nonactionable”

Prognostic Use

“That the test is not perfect and does not
determine outcome”

“Impact of information re: treatment/family/
prognosis and limitations of what can be
learned”

Registered Nurses

14

Genetic Counselors

5

Pathologists

5

Other (e.g. practice administrators, other physicians)

35

Total Participants

76

Conclusions
• Cancer care providers identify three main goals and elements of
provider-patient discussions to introduce GTT to patients:
1. Educate patients about the nature of the test including
scientific background, aspects of the testing process, and the
meaning of somatic vs. germline testing.
2. Convey the goals and purpose of GTT, largely focused on the
identifying actionable variants for treatment decisionmaking.
3. Manage patient expectations regarding the value of GTT.
• Providers describe the goals and purpose of GTT using mixed
language that conveys both the value of GTT and uncertainty
about its value.

• Replicate and assess the generalizability of the findings in a
larger, more diverse sample.
• Assess patients’ perceptions of the goals and ideal content of
physician-patient discussions of GTT.
• Develop and test patient education and decision support
interventions to facilitate informed and shared decision making
about GTT.
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Contact

Manage Patient Expectations
Assess and attend to patient “Basic knowledge/explanation of germline vs. somatic mutation (assess baseline health
literacy
literacy)”
Discuss likelihood of benefit

17

Future Research Directions

Nature of GTT

Goals and Purpose

Oncology Providers

“Benefits and limitations of the testing and how likely it is to provide information that would
lead to a therapeutic change, i.e. manage expectations”
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